NCT05948865 A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
| NCT ID | NCT05948865 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Conjupro Biotherapeutics, Inc. |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2023-06-06 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 132 participants in total. It began in 2023-06-06 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) * To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B) * To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To correlate preliminary efficacy with mutations in a biomarker called EGFR Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
Eligibility Criteria
Major Inclusion Criteria: * Age ≥18 years * Patients with histologically confirmed locally advanced or metastatic solid tumors who have disease progression, intolerance to prior therapy, are ineligible for available therapies, or refuse standard of care therapy in the metastatic setting. * In Part A, patients with solid tumors including but not limited to NSCLC (adenocarcinoma and squamous cell carcinoma), breast cancer, KRAS-wild type colorectal cancer, and head \& neck cancer based on previous biopsy result. * In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) suggested to have sensitivity to CPO301 in Part A. * At least 1 measurable target lesion present and documented by CT or MRI according to RECIST v1.1 * ECOG performance status 0 or 1 at screening * Life expectancy \>12 weeks Major Exclusion Criteria: * Known, active, or uncontrolled central nervous system (CNS) metastasis or carcinomatous meningitis. * Has AEs due to previous anti-tumor treatments not recovered to ≤Grade 1 (except for alopecia; some tolerable chronic toxicities of Grade 2 may be excluded after consultation with the sponsor, as judged by the investigator) according to NCI-CTCAE v5.0. * Any serious and/or uncontrolled concurrent illness that may interfere with study participation Prior therapy * Received other investigational drugs or treatments within 4 weeks before the first dose of the investigational drug in the study * The time interval between the latest anti-tumor treatment and the first dose of the investigational drug meets the following requirements: Have received anti-tumor treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy and other clinical investigational drugs within 4 weeks before the first dose of the investigational drug; have received oral fluoropyrimidines, small molecule targeted drugs within 2 weeks before the first dose of the investigational drug; have received palliative radiotherapy or local therapy within 2 weeks before the first dose of investigational drug. * Had major surgery within 4 weeks before the first dose of the investigational drug in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05948865 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05948865 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05948865 currently recruiting?
Yes, NCT05948865 is actively recruiting participants. Contact the research team at clinicaltrials.gov@cspcus.com for enrollment information.
Where is the NCT05948865 trial being conducted?
This trial is being conducted at Los Angeles, United States, Newport Beach, United States, Santa Monica, United States, Denver, United States and 10 additional locations.
Who is sponsoring the NCT05948865 clinical trial?
NCT05948865 is sponsored by Conjupro Biotherapeutics, Inc.. The trial plans to enroll 132 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.